Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

C4 Therapeutics (CCCC) FCF Margin: 2019-2025

Historic FCF Margin for C4 Therapeutics (CCCC) over the last 6 years, with Sep 2025 value amounting to -280.58%.

  • C4 Therapeutics' FCF Margin fell 12357.00% to -280.58% in Q3 2025 from the same period last year, while for Sep 2025 it was -314.80%, marking a year-over-year decrease of 10221.00%. This contributed to the annual value of -183.61% for FY2024, which is 33935.00% up from last year.
  • C4 Therapeutics' FCF Margin amounted to -280.58% in Q3 2025, which was down 50.40% from -186.55% recorded in Q2 2025.
  • In the past 5 years, C4 Therapeutics' FCF Margin registered a high of -43.07% during Q2 2024, and its lowest value of -1,072.81% during Q4 2022.
  • Over the past 3 years, C4 Therapeutics' median FCF Margin value was -346.30% (recorded in 2024), while the average stood at -428.81%.
  • In the last 5 years, C4 Therapeutics' FCF Margin crashed by 94,441bps in 2022 and then skyrocketed by 68,362bps in 2024.
  • Quarterly analysis of 5 years shows C4 Therapeutics' FCF Margin stood at -128.40% in 2021, then tumbled by 94,441bps to -1,072.81% in 2022, then soared by 33,175bps to -741.06% in 2023, then surged by 39,476bps to -346.30% in 2024, then tumbled by 12,357bps to -280.58% in 2025.
  • Its FCF Margin stands at -280.58% for Q3 2025, versus -186.55% for Q2 2025 and -459.86% for Q1 2025.